Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Sinovac Biotech ( (SVA) ).
On November 18, 2025, Sinovac Biotech disclosed that it received a Nasdaq delisting determination dated November 12, 2025, after failing to regain compliance with Nasdaq Listing Rule 5250(c)(1) by missing the November 11, 2025 extended deadline for filing its 2024 annual report on Form 20-F. The company attributed the filing delay to the April 15, 2025 resignation of its former auditor, Grant Thornton Zhitong, and said it has since appointed UHY LLP as its new independent registered public accounting firm and is working to complete the 2024 audit. Sinovac stated that it intends to request a hearing before a Nasdaq Hearing Panel by November 19, 2025 to appeal the delisting notice, a move that would automatically stay any suspension of trading for 15 days and could allow additional time to finish the overdue report, leaving investors facing continued uncertainty over the company’s U.S. listing status and financial transparency until the matter is resolved.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing and commercialization of vaccines against human infectious diseases. Its portfolio includes vaccines for COVID-19, hand-foot-mouth disease caused by EV71, hepatitis A, varicella, influenza, poliomyelitis and pneumococcal disease, with several products, such as its COVID-19 shot CoronaVac and hepatitis A vaccine Healive, holding World Health Organization prequalification or broad international approvals. The company supplies key pandemic influenza vaccines to the Chinese government and continues to invest in new and combination vaccines while pursuing expanded global market opportunities.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
See more insights into SVA stock on TipRanks’ Stock Analysis page.